Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Receives Consensus Recommendation of “Reduce” from Brokerages

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) have received an average recommendation of “Reduce” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $28.00.

Several brokerages recently issued reports on FMS. Wall Street Zen cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Jefferies Financial Group cut Fresenius Medical Care AG & Co. KGaA from a “moderate sell” rating to a “strong sell” rating in a research report on Tuesday, February 24th. Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday. Finally, Weiss Ratings cut Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, March 13th.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of FMS. Morgan Stanley boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% during the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company’s stock valued at $70,027,000 after buying an additional 942,497 shares during the last quarter. Pzena Investment Management LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock worth $339,592,000 after purchasing an additional 299,986 shares during the last quarter. Bank of America Corp DE boosted its position in Fresenius Medical Care AG & Co. KGaA by 279.7% in the second quarter. Bank of America Corp DE now owns 337,316 shares of the company’s stock worth $9,637,000 after purchasing an additional 248,477 shares during the last quarter. ABC Arbitrage SA boosted its position in Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the fourth quarter. ABC Arbitrage SA now owns 249,800 shares of the company’s stock worth $5,950,000 after purchasing an additional 229,589 shares during the last quarter. Finally, Integral Health Asset Management LLC boosted its position in Fresenius Medical Care AG & Co. KGaA by 44.4% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $15,483,000 after purchasing an additional 200,000 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.0%

NYSE FMS opened at $22.77 on Monday. The company has a market cap of $12.72 billion, a price-to-earnings ratio of 11.92, a P/E/G ratio of 2.77 and a beta of 0.89. Fresenius Medical Care AG & Co. KGaA has a 52 week low of $20.94 and a 52 week high of $30.46. The business has a 50 day moving average price of $23.01 and a 200-day moving average price of $23.69. The company has a quick ratio of 0.92, a current ratio of 1.26 and a debt-to-equity ratio of 0.40.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last announced its earnings results on Saturday, February 14th. The company reported $1.69 earnings per share (EPS) for the quarter. The company had revenue of $5.95 billion for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.73% and a net margin of 5.03%. As a group, equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.46 earnings per share for the current fiscal year.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.